The role of sarcopenic obesity for the prediction of prognosis of patients with gastrointestinal cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sarcopenic obesity (SO) significantly worsens survival in gastrointestinal cancer patients. Preoperative SO assessment aids in predicting 5-year survival and monitoring nutritional status for better patient outcomes.
Area Of Science
- Oncology
- Nutrition Science
- Body Composition Analysis
Background
- Sarcopenic obesity (SO) is linked to poor prognosis in gastrointestinal (GI) cancer.
- The prognostic impact and diagnostic criteria for SO in the Chinese population with GI cancer require investigation.
Purpose Of The Study
- To investigate the prognostic impact of sarcopenic obesity (SO) in Chinese patients with gastrointestinal cancer.
- To determine diagnostic cut-off values for SO in this population.
Main Methods
- A cohort study included 289 GI cancer patients (Jan 2017-Jan 2019).
- CT scans measured skeletal muscle and fat areas; ROC curves determined visceral fat obesity cut-offs for sarcopenia prediction.
- Patients were categorized into SO and non-SO (NSO) groups; survival analysis (Kaplan-Meier, Cox models) assessed body composition impact on 5-year survival.
Main Results
- Specific skeletal muscle index (SMI) and visceral fat area (VFA) cut-offs identified high-risk patients: men (SMI ≤40.02 cm²/m², VFA ≥126.30 cm²), women (SMI ≤32.05 cm²/m², VFA ≥72.42 cm²).
- SO patients exhibited significantly poorer 5-year overall survival (OS) (6.74% vs. 82.84%, p<0.001) and disease-specific survival (DSS) (6.74% vs. 81.82%, p<0.001) compared to NSO patients.
- Multivariate analysis revealed a ~13-fold higher mortality risk in the SO group versus non-SO patients.
Conclusions
- Preoperative assessment of sarcopenic obesity (SO) is crucial for predicting 5-year overall survival in GI cancer patients.
- SO evaluation aids in monitoring nutritional status, contributing to improved patient management and outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...